Skip to main content

What is the cost of Kymriah?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 3, 2022.

Official answer


According to Novartis, the manufacturer of Kymriah (tisagenlecleucel), this CAR-T cell cancer therapy costs $475,000 for one treatment course.

  • Kymriah is a chimeric antigen receptor T cell (CAR-T) therapy for use in pediatric and young adult patients (up to age 25) with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL).
  • It is also approved to treat relapsed or refractory large b-cell lymphoma in adults after two or more therapies.
  • In May 2022, the FDA approved Kymriah to treat adult patients with relapsed or refractory follicular lymphoma (FL).

This drug is usually given by a health care provider in a clinic or hospital and is not found in a traditional pharmacy. The cost for this medicine may be covered by your insurance but you may have a deductible, copay or coinsurance.

Does Medicare pay for Kymriah?

In August 2019, the Centers for Medicare & Medicaid Services (CMS) announced that CAR-T cell therapy would be covered for all patients with Medicare. You still may have copays or other costs.

Novartis supplies a tool on their website to search coverage for a specific state and insurance plan. Ask your physician for more information.

Most people do not pay out-of-pocket for the full price of Kymriah. Your cost will vary based on your insurance coverage or other financial assistance. Novartis may be able to provide this drug for free if you have been denied coverage or do not have insurance.

If you have more questions about Kymriah treatment, treatment center locations, or insurance coverage, you can contact Novartis at 1-844-4KYMRIAH (1-844-459-6742) for more information.


Related medical questions

Drug information

Related support groups